Equillium is keeping a close eye on the COVID-19 challenge, but sticking to acute GVHD, uncontrolled asthma, and lupus nephritis as primary inflammation targets.
ViralClear, formed in March 2020 to obtain a drug whose potential use against COVID-19 already has substantial support in evidence. The company is employing considerable industry expertise to move it into clinical development.
Spring Bank Pharmaceuticals is continuing clinical programs during the COVID-19 challenge and advancing novel approaches to cancer, inflammation, and viruses.
Argenx is developing new antibody therapeutics for immunological diseases in the neuromuscular, hematology, oncology, and other areas. The company has a full pipeline of candidates and indications.
Challenge breeds creativity, and a fresh example of that has emerged in Germany’s Ruhr Valley, with the company Abalos Therapeutics and the unique funding model that supported its launch.
This 10-person startup in San Diego is aiming for muscle-spasm relief without sedation in a purified drug.
Started in 2017, Eikonizo Therapeutics has led an uphill battle to getting funding for its pipeline that includes drugs for ALS and Alzheimer’s, among other neurodegenerative diseases.
This unlikely CEO’s experience offers some valuable lessons in founding and scaling up a biotech company, particularly one in a nascent space such as regenerative medicine.
Adaptive Phage Therapeutics has created a large catalog of bacteria-killing viruses combined with a diagnostic test to identify and target specific bacterial strains infecting individual patients.
In developing a new drug for MPN diseases, Imago is entering a space where two potential competitors, Jakafi and Inrebic, both JAK (janus associated kinase) inhibitors, are already on the market.
Get the latest articles from Life Science Leader delivered to your inbox.